Product logins

Find logins to all Clarivate products below.


John Stahl​

Partner​, US Pricing and Market Access​

John Stahl is a Partner with Clarivate’s Commercial Strategy Consulting team and leads the US Pricing and Market Access practice.​

John leverages over 20 years of deep healthcare knowledge as well as a broad range of market access and commercialization experience to effectively deliver strategic and actionable insights to biopharmaceutical and medtech clients. John has been with Clarivate for 10+ years, and during this time, he has supported clients with the development of market access landscape assessments, evidence generation and value communication strategies, pricing and contracting strategies, and account engagement strategies and tactics. His experience spans numerous TAs, with a concentration in cell and gene therapy, rare disease, oncology, immunology, and neurology conditions.​

Prior to joining Clarivate, John spent over ten years in the pharmaceutical industry working for Johnson & Johnson and Novartis, in a variety of positions of increasing responsibility, including business analytics, business development, sales, marketing, and managed markets.

John graduated from Duke University with a B.A. in Economics and a B.A. in German. He also completed the Certificate program in Markets and Management Studies.​


arrow_forward
Get in touch with John

Related resources

支付方愿意为便利性买单的市场准入“最佳切入点” 支付方愿意为便利性买单的市场准入“最佳切入点”
Blog June 3, 2026
支付方愿意为便利性买单的市场准入“最佳切入点”
医疗保险 定价 市场准入 真实世界数据 美国市场 药政法规
2026 年值得关注的 5 大医疗技术趋势 2026 年值得关注的 5 大医疗技术趋势
Blog May 28, 2026
2026 年值得关注的 5 大医疗技术趋势
AI/机器学习 GLP-1 医疗技术 带量采购(VBP) 日间手术中心(ASC)
《2026年最值得关注的药物》问答:礼来的下一代减肥药 《2026年最值得关注的药物》问答:礼来的下一代减肥药
Blog March 26, 2026
《2026年最值得关注的药物》问答:礼来的下一代减肥药
GLP-1 最值得关注的药物
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇 为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
Blog March 2, 2026
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
AI/机器学习 GLP-1 临床试验 交易 药政法规 衰老生物学